Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes.

Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly / Chiloiro, Sabrina; Costa, Denise; Lauretta, Rosa; Mercuri, Valeria; Sbardella, Emilia; Samperi, Irene; Appetecchia, Marialuisa; Bianchi, Antonio; Giampietro, Antonella; Gargiulo, Patrizia; Isidori, Andrea M; Poggi, Maurizio; Pontecorvi, Alfredo; De Marinis, Laura. - In: ENDOCRINE. - ISSN 1559-0100. - 78:2(2022), pp. 343-353. [10.1007/s12020-022-03158-w]

Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly

Costa, Denise;Mercuri, Valeria;Samperi, Irene;Gargiulo, Patrizia;Isidori, Andrea M;Pontecorvi, Alfredo;
2022

Abstract

Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes.
2022
GH; GH secreting pituitary adenoma; Growth hormone; IGF-I; Pasireotide; Pegvisomant
01 Pubblicazione su rivista::01a Articolo in rivista
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly / Chiloiro, Sabrina; Costa, Denise; Lauretta, Rosa; Mercuri, Valeria; Sbardella, Emilia; Samperi, Irene; Appetecchia, Marialuisa; Bianchi, Antonio; Giampietro, Antonella; Gargiulo, Patrizia; Isidori, Andrea M; Poggi, Maurizio; Pontecorvi, Alfredo; De Marinis, Laura. - In: ENDOCRINE. - ISSN 1559-0100. - 78:2(2022), pp. 343-353. [10.1007/s12020-022-03158-w]
File allegati a questo prodotto
File Dimensione Formato  
Chiloiro_Partial-response_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1652391
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact